EBEmilie C. H. Breekveldt

Emilie C. H. Breekveldt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Emilie C. H. Breekveldt has a total of 74 co-authors. Here are the top co-authors by number of shared publications:

  • Evelien Dekker

    Department of Gastroenterology and Hepatology, Amsterdam University Medical Centre – Location AMC, Amsterdam, the Netherlands

    5 shared publications
  • Anneke J. van Vuuren

    Department of Gastroenterology and Hepatology Erasmus University Medical Center Rotterdam The Netherlands

    4 shared publications
  • Esther Toes-Zoutendijk

    Department of Public Health, Erasmus MC University Medical Center, Rotterdam, Rotterdam, The Netherlands

    4 shared publications
  • Iris Lansdorp-Vogelaar

    Department of Public Health, Erasmus MC University Medical Center, Rotterdam, Rotterdam, The Netherlands

    4 shared publications
  • Iris Lansdorp-Vogelaar

    Department of Public Health Erasmus University Medical Center Rotterdam The Netherlands

    4 shared publications
  • Manon C. W. Spaander

    Department of Gastroenterology and Hepatology Erasmus University Medical Center Rotterdam The Netherlands

    4 shared publications

Latest Publications

  • Open Access

    Platinum retention in plasma, urine, and normal colonic mucosa in cisplatin-treated testicular cancer survivors

    by Emilie C. H. Breekveldt, Berbel L. M. Ykema, Alwin D. R. Huitema, Jourik A. Gietema, Jos H. Beijnen, Petur Snaebjornsson, Michael Schaapveld, Flora E. van Leeuwen, Hilde Rosing, Monique E. van Leerdam, et al.

    Testicular cancer survivors (TCS) treated with platinum-based chemotherapy have increased cancer risk. Platinum retention in healthy tissue may contribute to carcinogenesis. We assessed total platinum concentrations in plasma, urine, and normal colonic mucosa samples in TCS treated with cisplatin. From the total TCS treated with ≥3 cycles cisplatin who participated in a colonoscopy-screening study in four Dutch hospitals (n = 154), plasma (n = 131) and urine (n = 115) samples were collected. During colonoscopy, 60 biopsies of normal colonic mucosa (two samples each per 30 randomly selected patients undergoing colonoscopy) were obtained. Samples were analyzed for total platinum concentrations using inductively coupled plasma mass spectrometry and compared with controls (plasma: 10, urine: 3, normal colonic mucosa: 9). The median age at colonoscopy was 50 years (interquartile range (IQR): 43–57) and the median time since treatment was 20 years (IQR:16–26). Median platinum concentrations in plasma (38 pg/mL; IQR: 24–61 pg/mL) and urine (376 pg/mL; IQR: 208–698 pg/mL) remained elevated in TCS up to 40 years post-treatment and were higher than in controls (all controls were below limits of detection [plasma: 25 pg/mL, urine: 6 pg/mL]). The median platinum concentration in normal colonic mucosa was 0.58 pg/mg (IQR: 0.33–1.59 pg/mg) in the transverse and 0.51 pg/mg (IQR:0.26–1.25 pg/mg) in the descending colon. Cisplatin treatment is associated with long-term retention of platinum in various patient sample types. This might increase cancer risk by causing somatic mutations, potentially explaining the elevated risk of second malignant neoplasms in TCS. The long-term effects of platinum retention should be monitored to understand carcinogenesis and to provide guidelines for early second cancer detection. Trial registration: ClinicalTrials.Gov: NCT04180033.


  • Open Access

    Prevalence of neoplasia at colonoscopy among testicular cancer survivors treated with platinum‐based chemotherapy

    by Emilie C. H. Breekveldt, Berbel L. M. Ykema, Tanya M. Bisseling, Leon M. G. Moons, Manon C. W. Spaander, Inge L. Huibregtse, Dorien T. J. van der Biessen‐Van Beek, Sasja F. Mulder, Lisette Saveur, J. Martijn Kerst, et al.

    Testicular cancer survivors (TCS) treated with platinum‐based chemotherapy have an increased risk of colorectal cancer (CRC). We determined the yield of colonoscopy in TCS to assess its potential in reducing CRC incidence and mortality. We conducted a colonoscopy screening study among TCS in four Dutch hospitals to assess the yield of colorectal neoplasia. Neoplasia was defined as adenomas, serrated polyps (SPs), advanced adenomas (AAs: ≥10 mm diameter, high‐grade dysplasia or ≥25% villous component), advanced serrated polyps (ASPs: ≥10 mm diameter or dysplasia) or CRC. Advanced neoplasia (AN) was defined as AA, ASP or CRC. Colonoscopy yield was compared to average‐risk American males who underwent screening colonoscopy (n = 24,193) using a propensity score matched analysis, adjusted for age, smoking status, alcohol consumption and body mass index. A total of 137 TCS underwent colonoscopy. Median age was 50 years among TCS (IQR 43–57) vs 55 years (IQR 51–62) among American controls. A total of 126 TCS were matched to 602 controls. The prevalence of AN was higher in TCS than in controls (8.7% vs 1.7%; P = .0002). Nonadvanced adenomas and SPs were detected in 45.2% of TCS vs 5.5% of controls (P < .0001). No lesions were detected in 46.0% of TCS vs 92.9% of controls (P < .0001). TCS treated with platinum‐based chemotherapy have a higher prevalence of neoplasia and AN than matched controls. These results support our hypothesis that platinum‐based chemotherapy increases the risk of colorectal neoplasia in TCS. Cost‐effectiveness studies are warranted to ascertain the threshold of AN prevalence that justifies the recommendation of colonoscopy for TCS.


  • Open Access

    Personalized colorectal cancer screening: study protocol of a mixed-methods study on the effectiveness of tailored intervals based on prior f-Hb concentration in a fit-based colorectal cancer screening program (PERFECT-FIT)

    by Emilie C. H. Breekveldt, Esther Toes-Zoutendijk, Lucie de Jonge, Manon C. W. Spaander, Evelien Dekker, Folkert J. van Kemenade, Anneke J. van Vuuren, Christian R. B. Ramakers, Iris D. Nagtegaal, Monique E. van Leerdam, et al.

    Background: In 2014, the national population-based colorectal cancer (CRC) screening program was implemented in the Netherlands. Biennial fecal immunochemical testing (FIT) for hemoglobin (Hb) is used at a cut-off of 47 µg Hb per gram feces. The CRC screening program successfully started, with high participation rates and yield of screening. Now that the program has reached a steady state, there is potential to further optimize the program. Previous studies showed that prior fecal Hb (f-Hb) concentrations just below the FIT cut-off are associated with a higher risk for detection of advanced neoplasia (AN) at subsequent screening rounds. We aim to achieve a better balance between the harms and benefits of CRC screening by offering participants tailored invitation intervals based on prior f-Hb concentrations after negative FIT.Methods: This mixed-methods study will be performed within the Dutch national CRC screening program and will consist of: (1) a randomized controlled trial (RCT), (2) focus group studies, and (3) decision modelling. The primary outcome is the yield of AN per screened individual in personalized screening vs. uniform screening. Secondary outcomes are perspectives on, acceptability of and adherence to personalized screening, as well as long-term outcomes of personalized vs. uniform screening. The RCT will include 20,000 participants of the Dutch CRC screening program; 10,000 in the intervention and 10,000 in the control arm. The intervention arm will receive a personalized screening interval based on the prior f-Hb concentration (1, 2 or 3 years). The control arm will receive a screening interval according to current practice (2 years). The focus group studies are designed to understand individuals’ perspectives on and acceptability of personalized CRC screening. Results of the RCT will be incorporated into the MISCAN-Colon model to determine long-term benefits, harms, and costs of personalized vs. uniform CRC screening.Discussion: The aim of this study is to evaluate the yield, feasibility, acceptability and (cost-) effectiveness of personalized CRC screening through tailored invitation intervals based on prior f-Hb concentrations. This knowledge may be of guidance for health policy makers and may provide evidence for implementing personalized CRC screening in The Netherlands and/or other countries using FIT as screening modality.Trial registration:ClinicalTrials.gov, NCT05423886, June 21, 2022,https://clinicaltrials.gov/ct2/show/NCT05423886


  • Open Access

    Personalized Colorectal Cancer Screening: Study Protocol of a Mixed-methods Study on the Effectiveness of Tailored Intervals Based on Prior F-hb Concentration in a Fit-based Colorectal Cancer Screening Program

    by Emilie C. H. Breekveldt, Esther Toes-Zoutendijk, Lucie de Jonge, Manon C. W. Spaander, Evelien Dekker, Folkert J. van Kemenade, Anneke J. van Vuuren, Christian R. B. Ramakers, Iris D. Nagtegaal, Monique E. van Leerdam, et al.

    Background: In 2014, the national population-based colorectal cancer (CRC) screening program was implemented in the Netherlands. Biennial fecal immunochemical testing (FIT) for hemoglobin is used at a cut-off of 47 microgram hemoglobin per gram feces. The CRC screening program successfully started, with high participation rates and yield of screening. Now that the program has reached a steady state, there is potential to further optimize the program. Previous studies showed that prior fecal Hb (f-Hb) concentrations just below the FIT cut-off are associated with a higher risk for detection of advanced neoplasia (AN) at subsequent screening rounds. We aim to achieve a better balance between the harms and benefits of CRC screening by offering participants tailored invitation intervals based on prior f-Hb concentrations after negative FIT. Methods: This mixed-methods study will be performed within the Dutch national CRC screening program and will consist of: 1) a randomized controlled trial (RCT), 2) focus group studies, and 3) decision modelling. The primary outcome is the yield of AN per screened individual in personalized screening vs. uniform screening. Secondary outcomes are perspectives on, acceptability of and adherence to personalized screening, as well as long-term outcomes of personalized vs. uniform screening. The RCT will include 20,000 participants of the Dutch CRC screening program; 10,000 in the intervention and 10,000 in the control arm. The intervention arm will receive a personalized screening interval based on the prior f-Hb concentration (1, 2 or 3 years). The control arm will receive a screening interval according to current practice (2 years). The focus group studies are designed to understand individuals’ perspectives on and acceptability of personalized CRC screening. Results of the RCT will be incorporated into the MISCAN-Colon model to determine long-term benefits, harms, and costs of personalized versus uniform CRC screening. Discussion: The aim of this study is to evaluate the yield, feasibility, acceptability and (cost-) effectiveness of personalized CRC screening through tailored invitation intervals based on prior f-Hb concentrations. This knowledge may be of guidance for health policy makers and may provide evidence for implementing personalized CRC screening in The Netherlands and/or other countries using FIT as screening modality. Trial registration: Clinical Trials, NCT05423886, June 21, 2022, https://clinicaltrials.gov/ct2/show/NCT05423886

  • Open Access

    Factors associated with interval colorectal cancer after negative FIT: Results of two screening rounds in the Dutch FIT‐based CRC screening program

    by Emilie C. H. Breekveldt, Esther Toes‐Zoutendijk, Hilliene J. van de Schootbrugge‐Vandermeer, Lucie de Jonge, Arthur I. Kooyker, Manon C. W. Spaander, Anneke J. van Vuuren, Folkert J. van Kemenade, Christian Ramakers, Evelien Dekker, et al.

    The interval colorectal cancer (CRC) rate after negative fecal immunochemical testing (FIT) is an important quality indicator of CRC screening programs. We analyzed the outcomes of two rounds of the FIT‐based CRC screening program in the Netherlands, using data from individuals who participated in FIT‐screening from 2014 to 2017. Data of individuals with one prior negative FIT (first round) or two prior negative FITs (first and second round) were included. Outcomes included the incidence of interval CRC in FIT‐negative participants (40‐46.9 μg/g) had a higher probability of detecting an interval CRC (OR 16.9; 95%CI: 14.0‐20.4) than had participants with unmeasurable f‐Hb (0‐2.6 μg/g). After two screening rounds, the odds ratio for interval CRC was 12.0 (95%CI: 7.8‐17.6) for participants with f‐Hb just below the cut‐off compared with participants with unmeasurable f‐Hb. After both screening rounds, the Dutch CRC screening program had a low incidence of interval CRC and an associated high FIT‐sensitivity. Our findings suggest there is a potential for further optimizing CRC screening programs with the use of risk‐stratified CRC screening based on prior f‐Hb.


  • Open Access

    Advanced-stage CRC incidence patterns following the phased implementation of the CRC screening programme in the Netherlands

    by Emilie C.H. Breekveldt, Esther Toes-Zoutendijk, Manon C.W. Spaander, Hilliene J. van de Schootbrugge-Vandermeer, Anneke J. van Vuuren, Folkert J. van Kemenade, Christian R.B. Ramakers, Evelien Dekker, Iris D. Nagtegaal, Monique E. van Leerdam, et al.


  • Open Access

    Modelling optimal use of temporarily restricted colonoscopy capacity in a FIT-based CRC screening program: Application during the COVID-19 pandemic

    by Lucie de Jonge, Hilliene J. van de Schootbrugge-Vandermeer, Emilie C. H. Breekveldt, Manon C. W. Spaander, Hanneke J. van Vuuren, Folkert J. van Kemenade, Evelien Dekker, Iris D. Nagtegaal, Monique E. van Leerdam, Iris Lansdorp-Vogelaar

    Objective: The COVID-19 pandemic forced colorectal cancer (CRC) screening programs to downscale their colonoscopy capacity. In this study, we assessed strategies to deal with temporary restricted colonoscopy capacity in a FIT-based CRC screening program while aiming to retain the maximum possible preventive effect of the screening program. Design: We simulated the Dutch national CRC screening program inviting individuals between ages 55 and 75 for biennial FIT using the MISCAN-Colon model including the 3-month disruption in the first half of 2020 due to the COVID-19 pandemic. For the second half of 2020 and 2021, we simulated three different strategies for the total target population: 1) increasing the FIT cut-off, 2) skipping one screening for specific screening ages, and 3) extending the screening interval. We estimated the impact on required colonoscopy capacity in 2020–2021 and life years (LYs) lost in the long-term. Results: Increasing the FIT cut-off, skipping screening ages and extending the screening interval resulted in a maximum reduction of 25,100 (-17.0%), 16,100(-10.9%) and 19,000 (-12.9%) colonoscopies, respectively. Modelling an increased FIT cut-off, the number of LYs lost ranged between 1,400 and 4,400. Skipping just a single screening age resulted in approximately 2,700 LYs lost and this was doubled in case of skipping two screening ages. Extending the screening interval up to 34 months had the smallest impact on LYs lost (up to 1,100 LYs lost). Conclusion: This modelling study shows that to anticipate on restricted colonoscopy capacity, temporarily extending the screening interval retains the maximum possible preventive effect of the CRC screening program.


  • Open Access

    Faecal occult blood loss accurately predicts future detection of colorectal cancer. A prognostic model

    by Reinier G S Meester, Hilliene J van de Schootbrugge-Vandermeer, Emilie C H Breekveldt, Lucie de Jonge, Esther Toes-Zoutendijk, Arthur Kooyker, Daan Nieboer, Christian R Ramakers, Manon C W Spaander, Anneke J van Vuuren, et al.

    Objectives To examine the prognostic potential of repeated faecal haemoglobin (F-Hb) concentration measurements in faecal immunochemical test (FIT)-based screening for colorectal cancer (CRC). Design Prognostic model. Setting Dutch biennial FIT-based screening programme during 2014–2018. Participants 265 881 participants completing three rounds of FIT, with negative test results (F-Hb Interventions Colonoscopy follow-up in participants with a positive FIT (F-Hb ≥47 µg Hb/g faeces). Main outcomes We evaluated prognostic models for detecting advanced neoplasia (AN) and CRC in round 3, with as predictors, participant age, sex, F-Hb in rounds 1 and 2, and categories/combinations/non-linear transformations of F-Hb. Primary evaluation criteria included: risk prediction accuracy (calibration), discrimination of participants with versus without AN or CRC (optimism-adjusted C-statistics, range 0.5–1.0), the degree of risk stratification and C-statistics in external validation. Results Among study participants, 8806 (3.3%) had a positive FIT result, 3254 (1.2%) had AN detected and 557 (0.2%) had cancer. F-Hb concentrations in rounds 1 and 2 were the strongest outcome predictors, with adjusted ORs of up to 9.4 (95% CI 7.5 to 11.7) for the highest F-Hb category. Risk predictions matched the observed risk for most participants (calibration intercept −0.008 to −0.099; slope 0.982–0.998), and discriminated participants with versus without AN or CRC with C-statistics of 0.78 (95% CI 0.77 to 0.79) and 0.73 (95% CI 0.71 to 0.75), respectively. The predicted risk ranged from 0.4% to 36.7% for AN and from 0.0% to 5.5% for CRC across participants. In external validation, the model retained similar discrimination accuracy for AN (C-statistic 0.77, 95% CI 0.66 to 0.87) and CRC (C-statistic 0.78, 95% CI 0.66 to 0.91). Conclusion Participants at lower versus higher risk of future AN or CRC can be accurately identified based on their age, sex and particularly, prior F-Hb concentrations. Risk stratification should be considered based on this information.


  • Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a population-based study

    by Emilie C H Breekveldt, Iris Lansdorp-Vogelaar, Esther Toes-Zoutendijk, Manon C W Spaander, Anneke J van Vuuren, Folkert J van Kemenade, Christian R B Ramakers, Evelien Dekker, Iris D Nagtegaal, Myrtle F Krul, et al.